Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus REVONTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus REVONTO.
CHLORZOXAZONE vs REVONTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
4 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
Terminal elimination half-life is approximately 18–20 hours in healthy adults, allowing once-daily dosing.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Renal excretion of unchanged drug accounts for <1% of the dose; fecal excretion via biliary elimination is the primary route (≈90%), with the remainder as metabolites.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."